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EDITORIAL
Polycystic kidney disease: A new perspective from the beginning
Mutations in PKD 1 or PKD 2 cause autosomal-dominant
polycystic kidney disease (ADPKD), the most common
monogenetic hereditary kidney disease worldwide [1, 2].
It is estimated that at least 12 million people have the gene
defect, and PKD is the fourth leading cause of end-stage
renal disease (ESRD) in the United States (about 85%
having PKD 1 and approximately 15% having a PKD 2
mutation). In ADPKD, cystogenesis begins in utero and
the relentless process continues over the lifetime of the
affected individual. Accelerated proliferation of cells that
line enlarging fluid-filled cyst cavities steadily compress
normal parenchyma and eventuate in a progressive loss
of kidney function after many decades [3]. Those indi-
viduals with PKD1 who develop eventual kidney failure
requiring renal replacement therapy (RRT) are in their
early 50s on average. Patients with PKD 2 generally re-
quire RRT more than a decade later, if such is needed
[4].
When are cysts first clinically evident in patients with
ADPKD and what is the significance of early versus
later detection of cysts in this population? In this is-
sue of Kidney International, Shamshirsaz et al [5] exam-
ined the University of Colorado Health Sciences Center
ADPKD database to compare clinical characteristics
between groups with the appearance of cysts before
18 months of age versus those whose cysts appeared
between 18 months and 18 years of age. Five percent
of their 895 subjects with ADPKD had cysts noted be-
fore 18 months of age, and 16% of children from this
cohort had cysts noted between ages 18 months and
18 years. Not unexpected, the earlier the onset of cyst
formation, the larger the renal volume when adjusted
for age. Hypertension and left ventricular mass index ap-
pear to correlate with the earliest detection of cyst for-
mation. Complicating features of proteinuria, hematuria,
and signs/symptoms attributed to ADPKD are associated
with larger age-adjusted renal volumes, no matter if the
cysts are detected very early or later in childhood.
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While the numbers are small, ESRD occurred in two of
the children with the earliest appearance of kidney cysts.
The majority of PKD children who progress to ESRD
carry the diagnosis of autosomal-recessive polycystic kid-
ney disease (ARPKD) and not ADPKD. It was encour-
aging to note that during the 20 years of data collection by
the University of Colorado group committed to studying
PKD, renal function generally remained well preserved
during childhood in those individuals with very early on-
set of cyst formation.
It is known that ADPKD is characterized by both large
inter- and intrafamilial variability. Much of the intrafamil-
ial variability is thought to be due to the effect of modifier
genes [6]. The longest follow-up study to date in children
with ADPKD was done by Tee et al [7]. Phenotypic het-
erogeneity was examined in children, with the family his-
tory of ADPKD being the factor that led to diagnostic
imaging in these children. During the 20-year follow-up
in 55 children, renal function was not significantly dimin-
ished in the vast majority of subjects. This observation
dovetails with that reported by Shamshiraz et al. It was
interesting to note that this cohort of children studied
by Tee et al had hyperlipidemia, hypertension (not well
controlled in many of the subjects with treatment), and in-
frequent proteinuria. These complicating conditions did
not appear to impact kidney function during the 20-year
follow-up. The conclusion of these authors was that many
children at the time of presentation have risk factors that
are modifiable, but kidney function is not impaired.
When considering the natural course history for the
“clinical” appearance of kidney disease (i.e., decline in
kidney function and distorted kidney size with massive
cysts) in patients with ADPKD, the 20-year time frame is
a relatively “short” follow-up. It would not be surprising
if the individuals with the earliest expression of cysto-
genesis and larger renal volumes are those who develop
kidney failure earlier than the sixth decade of life.
Monitoring progression of PKD has been made eas-
ier by noninvasive magnetic resonance imaging (MRI)
(with gadolinium enhancement). The Consortium for Re-
nal Imaging in Polycystic Kidney Disease (CRISP) is
a cooperative study designed to demonstrate that MRI
can accurately measure kidney volume and cyst vol-
ume, and determine if these changes correlate with a
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decline in kidney function over the period observed [8].
A secondary goal of the CRISP Study is to determine
whether renal blood flow (RBF) can be accurately and
reproducibly measured by MRI over a short period [9].
As above, the goal is to determine if RBF changes corre-
late with changes in kidney function. Validation studies
have shown that these measurements can be accurately
and reproducibly achieved. As kidney volume increases,
glomerular filtration rate (GFR) decreases. Kidney vol-
umes are directly related to the presence of hypertension
and urinary albumin excretion [10]. RBF is inversely re-
lated to total kidney and cyst volumes and directly related
to GFR indices of disease severity.
Current knowledge should correct physician miscon-
ception that PKD does not have an impact until late in
life. GFR remains normal over many years because of a
compensatory increase in GFR by nephrons that are not
involved in cystogenesis and not because the disease is
stable or quiescent.
The cohort of children studied by Shamshirsaz et al did
not have the benefit of MR technology to determine the
rate of increase in kidney volume and correlate it with
changes in GFR. As children are screened for the pres-
ence of ADPKD (the impetus for study being a family
history of this disorder), the MRI will be able to accu-
rately detect renal volume, cyst volume, and renal blood
flow. Anatomic and functional correlations will allow for
more accurate assessment of patients. As therapeutic in-
terventions become available, hopefully they can be in-
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